Cancer Research Blog

Bringing You the Latest in the Search For a Cure

Month: June 2016

Enhanced Risk-Based Lung Cancer Screening May Prevent More Deaths than Current Approaches

NCI researchers have developed a risk model-based approach for selecting smokers and former smokers who may be candidates for lung cancer screening with low-dose computed tomography (CT). Using data from two lung cancer screening studies and a U.S. health survey, the researchers estimated that the new approach might prevent more deaths from lung cancer over 5 years than would current screening recommendations.

Results from the statistical analysis appeared in JAMA on May 15. 

Two New Therapies Approved by FDA for Advanced Kidney Cancer

The Food and Drug Administration (FDA) recently approved two drugs for the treatment of patients with advanced kidney cancer. Both approvals are for patients whose cancers have progressed after receiving prior treatment with drugs that block tumor blood vessel growth, known as antiangiogenic therapies.

On April 15, the agency approved cabozantinib (Cabometyx™), and on May 13 it approved lenvatinib (Lenvima®) in combination with everolimus (Afinitor®).

NCI and the Chinese National Cancer Center pursue new collaborations in cancer research

The NCI Center for Global Health (CGH) has been working closely with the Chinese government, including the Chinese National Cancer Center (NCC), to strengthen cancer research in the U.S. and China.    

CGH Director, Dr. Ted Trimble, and East Asia Program Director, Dr. Ann Chao, traveled to Beijing with Mr. Matthew Brown from the Department of Health and Human Services Office of Global Affairs to attend the Joint Meeting of the NCC and the U.S. NCI, held on April 22nd.  This joint meeting occurs annually and alternates between the United States and China. This year the group discussed cooperation in the areas of colorectal cancer screening, microbiome research, and joint clinical research activities in immunotherapy.  

Patient-Derived Antibody Appears to Selectively Target Tumor Cells, Spur Immune Attack

Researchers have developed an antibody derived from patients with early-stage lung cancer that enlists the immune system to destroy cancer cells.

The antibody killed tumor cells in cell lines of several different cancer types and slowed tumor growth in mouse models of brain and lung cancer without obvious evidence of side effects, the researchers reported May 5 in Cell Reports.

Cancer Research Blog © 2016
Contact: jim@jdgblogs.com
Frontier Theme
yes